// App-Quantinova.ai

164 : Phase I trial of metronomic cyclophosphamide (CTX) and lenalidomide (LEN) in patients with castration-resistant prostate cancer (CRPC).

Researchers

Presenter

  • Jue Wang

Principal Investigators

  • Timothy R. McGuire

  • James K. Schwarz

  • Jane L Meza

  • James E E Talmadge

Medical Centers

  • University of Nebraska Medical Center, Omaha, NE

  • University of Nebraska, Omaha, NE

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

  • Tuberculosis

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Regulatory T cells

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Lenalidomide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved